Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data
Modern Rheumatology · 02.03.2023 · 33 (2) · 302-311
DOI: 10.1093/mr/roac038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, online erschienen am 21.04.2022. Verfasst von Masataka Kuwana und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8602, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Biological Products. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To assess the cost-effectiveness of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) in rheumatoid arthritis.
Methods
We conducted three analyses: a lifetime analysis with a cohort model (Study A) and two short-term analyses (Studies B and C). Study A evaluated the incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) gained from costs of standard treatments. Study B evaluated yearly costs per person achieving American College of Rheumatology (ACR) response (ACR20, ACR50, and ACR70), and Study C evaluated costs per person achieving previously defined claims-based effectiveness (equivalent to 28-joint Disease Activity Score ≤ 3.2). The proportion of ACR responders to the drugs of interest were determined by mixed treatment comparisons. Studies B and C estimated costs using a claims database.
Results
In Study A, ICERs of all b/tsDMARDs were lower than 5.0 million Japanese yen (JPY) per QALY. In Study B, yearly costs per person with ACR50 response were lower for subcutaneous tocilizumab (TCZ-SC; 1.9 million JPY) and SC abatacept (2.3 million JPY). In Study C, costs per person were lower for TCZ-SC (1.3 million JPY) and intravenous TCZ (1.6 million JPY) and effectiveness rates were higher for intravenous TCZ (45.3%) and infliximab (43.0%).
Conclusion
The b/tsDMARDs with lower prices showed higher cost-effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8602, Japan.
- Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
- Department of Rheumatology, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan.
- Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.
- Medilead Inc., Tokyo Opera City Tower, Shinjuku-ku, Tokyo 163-1424, Japan.
- Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo 103-8324, Japan.
ORCID-Profile: Masataka Kuwana
Zitieren
APA
Kuwana, M., Tamura, N., Yasuda, S., Fujio, K., Shoji, A., Yamaguchi, H., Iwasaki, K., Makishima, M., Kawata, Y., Yamashita, K., & Igarashi, A. (2023). Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data. Modern Rheumatology, 33(2), 302-311. https://doi.org/10.1093/mr/roac038
Vancouver
Kuwana M, Tamura N, Yasuda S, Fujio K, Shoji A, Yamaguchi H, et al. Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data. Modern Rheumatology. 2023;33(2):302-311. doi:10.1093/mr/roac038
BibTeX
@article{Kuwana2023,
author = {Kuwana, Masataka and Tamura, Naoto and Yasuda, Shinsuke and Fujio, Keishi and Shoji, Ayako and Yamaguchi, Hiroko and Iwasaki, Katsuhiko and Makishima, Misako and Kawata, Yuichi and Yamashita, Katsuhisa and Igarashi, Ataru},
title = {Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data},
journal = {Modern Rheumatology},
year = {2023},
volume = {33},
number = {2},
pages = {302--311},
doi = {10.1093/mr/roac038}
}
EUVIMED